Biological targeting

Initiating biologics and biosimilars in practice: approach and consultation guidance

Considerations for initiating biologic and biosimilar medicines, including the relevant clinical pathways and patient counselling.…

Ten things pharmacists should know about biologics and biosimilars

As healthcare professionals prepare for blockbuster biologic Humira to come off patent on 16 October 2018, we highlight what pharmacists need to know about switching from originator biologics to biosimilars in order to get the best value from these medicines.…

Body bionics: how the next generation of biosensors could revolutionise drug delivery

Smaller, smarter and more sensitive — how four new technologies could change the way drugs are monitored and administered.…

Preparing for the big biologic switch

With blockbuster biologic adalimumab coming off patent in October 2018, pharmacists should be ready to switch patients to the best-value biologic as alternatives become available.…

Innovation in acne treatment is long overdue but the treatment pipeline looks promising

Current treatments for acne are effective but regimens are complex and side effects are common. Better understanding of the pathology of acne is leading to identification of new, safer, treatment targets, and dermatologists and researchers in the field are excited about the pipeline.…

Making drugs work better: four new drug delivery methods

New drug delivery methods have started to emerge that aim to improve efficacy, cost-effectiveness and adherence as well as reduce side effects.…

Making drugs work better: four new drug delivery methods

New drug delivery methods have started to emerge that aim to improve efficacy, cost-effectiveness and adherence as well as reduce side effects.…

Psoriasis drug approved by FDA

The US Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis…

FDA approves first treatment for giant cell arteritis

Subcutaneous tocilizumab (marketed as Actemra) has been approved by the US drug safety watchdog to treat adults with giant cell arteritis, a type of vasculitis.…

Informative video about biosimilar medicines for patients

The National Rheumatoid Arthritis Society (NRAS) has put together a video about biosimilar medicines which are entering the UK market as originator biologic medicines come off-patent. We want to encourage pharmacists and their staff to signpost suitable patients who are currently being prescribed bi…